BNGO
Bionano Genomics·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BNGO
Bionano Genomics, Inc.
A company that develops saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection
9540 Towne Centre Drive
, Suite 100
, San Diego
, CA 92121
Provides genome analysis solutions for life science instruments.
Bionano Genomics, Inc., was incorporated in Delaware on August 16, 2007. The company is a provider of genome analysis solutions, including optical genome mapping systems, nucleic acid extraction and purification platforms, and data analysis software. Its products serve basic, translational and clinical research applications, as well as diagnostic testing services.
Company Financials
EPS
BNGO has released its 2026 Q2 earnings. EPS was reported at -0.67, versus the expected -0.67, meeting expectations. The chart below visualizes how BNGO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BNGO has released its 2026 Q2 earnings report, with revenue of 8.17M, reflecting a YoY change of 21.36%, and net profit of -7.42M, showing a YoY change of -8.25%. The Sankey diagram below clearly presents BNGO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
